“…The PBR protein is overexpressed in some tumors, and this overexpression has a negative prognostic impact on breast cancer and colorectal cancer (Maaser et al, 2005). In contrast, knockdown of PBR expression by an antisense construct enhances the tumorigenicity of murine cancer cell lines (Weisinger et al, 2004). Ligation of PBR with synthetic ligands such as 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) or 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (Ro5-4864) facilitates apoptosis induction in human tumor cells by a variety of chemotherapeutic agents, including doxorubicin (Hirsch et al, 1998;Sutter et al, 2004), daunorubicin (Jakubikova et al, 2002), etoposide (Decaudin et al, 2002;Okaro et al, 2002), 5-fluorouracil, UV and g-irradiation (Okaro et al, 2002), ifosfamide (Decaudin et al, 2002), paclitaxel, docetaxel (Hirsch et al, 1998;Sutter et al, 2004), colchicine (Jorda et al, 2005), arsenicals (Larochette et al, 1999;Muscarella et al, 2003), lonidamine (Ravagnan et al, 1999), and bortezomib (Chauhan et al, 2004).…”